One hundred and sixty patients having bronchogenic carcinoma were evaluated for bone metastasis by means of 99mTc-monodiphosphate bone scanning, correlative radiographic bone survey and their clinical findings. In all patients, diagnosis was histologically proved. Bone scan demonstrated the possible evidence of bone metastasis in 75 patients (46.9%) and radiography, in 29 patients (18.1%). False negative was noted in 1 patient-Bone scan correlated with radiography in 37.3%, and with accompanying bone pain in 52% of the patients. But there was no correlation with the level of serum calcium, inorganic phos- phorus and alkaline phosphatase. In connection with their clinical stages before scanning, bone scans were positive in 33.3% of clinical stage I, 10.8% of clinica1 stage II and 54.1% of clinical stage III. Our Study suggests that bone scanning with 99m-monodiphosphate detected early bone metastasis in patients with bronchogenic carcinoma before their lesions became evident clinically or radiographically, and also important to determine operability.
Adult ; Aged ; Bone Neoplasms/radiography ; Bone Neoplasms/radionuclide imaging ; Bone Neoplasms/secondary* ; Bone and Bones/radionuclide imaging* ; Carcinoma, Bronchogenic/radiography ; Carcinoma, Bronchogenic/radionuclide imaging* ; Comparative Study ; Female ; Human ; Lung Neoplasms/radiography ; Lung Neoplasms/radionuclide imaging* ; Male ; Middle Age ; Technetium/diagnostic use ; Tomography, Emission-Computed

This is a case of a 54-year-old male, diagnosed to have insular thyroid carcinoma. The histopathologic characteristic of this rare neoplasm arising from follicular epithelial cells has the potential to take up 1-131 As shown in his postoperative 1-131 imaging, there are iodine-avid lesions in the parietal bone, thyroidal beds, ribs and vertebrae. The presence of these lesions in a &agnostic radioactive iodine scan makes it possible to do radioactive iodine therapy. A follow-up diagnostic study with 1-131 shows interval resolution and regression of the metastatic lesions. Thus, radioactive iodine therapy has a role in the treatment of this rare and aggressive neoplasm.

Human ; Male ; Middle Aged ; Iodine ; Parietal Bone ; Thyroid Neoplasms ; Iodides ; Radionuclide Imaging ; Ribs ; Epithelial Cells

This is a case of a 54-year-old male, diagnosed to have insular thyroid carcinoma. The histopathologic characteristic of this rare neoplasm arising from follicular epithelial cells has the potential to take up 1-131 As shown in his postoperative 1-131 imaging, there are iodine-avid lesions in the parietal bone, thyroidal beds, ribs and vertebrae. The presence of these lesions in a &agnostic radioactive iodine scan makes it possible to do radioactive iodine therapy. A follow-up diagnostic study with 1-131 shows interval resolution and regression of the metastatic lesions. Thus, radioactive iodine therapy has a role in the treatment of this rare and aggressive neoplasm.

Human ; Male ; Middle Aged ; Iodine ; Parietal Bone ; Thyroid Neoplasms ; Iodides ; Radionuclide Imaging ; Ribs ; Epithelial Cells

Malignant bone tumors would be classified as primary malignant bone tumors, secondary malignant bone tumors, and metastatic bone tumors. Primary malignant bone tumors are rare diseases occupying 1% of adult cancers, and 6% of pediatric cancers. The chief complaint of malignant bone tumor patients is pain different from that of malignant soft tissue tumor patients. Diagnostic procedures start with clinical evaluation including current illness, past medical history, family history, and physical examination. Then we take a radiograph first and obtain important and diagnostic clues from it. However pathological diagnosis and information about the extent of tumor are required to obtain a more definite diagnosis and staging. Examinations for detection of local and systemic tumor extent are scintigraphy, computed tomography (CT), magnetic resonance imaging, and positron emission tomography-CT. If the clinical and radiographic information suggests aggressive or malignant bone tumor, the patient should be referred to a bone tumor specialist without further evaluations.
Adult ; Biopsy ; Bone Neoplasms ; Diagnosis ; Electrons ; Humans ; Magnetic Resonance Imaging ; Physical Examination ; Radionuclide Imaging ; Rare Diseases ; Specialization

Patient with osseous metastatic prostatic cancer can clinically be detected by bone scanning, which usually is sensitive and qualitative but is not specific and quantitative. For quantitative evaluation of skeletal lesions, we measured bone mineral density (BMD) in whole body, total spine and lumbar spine. All patients also were assessed with bone radiography, radionuclide bone scan, prostate specific antigen (PSA), and prostatic acid phosphatase (PAP). We compared mainly bone scan and BMD in monitoring tumor response between before hormonal treatment and 6 month after hormonal treatment. Fifteen patients with stage D2 prostate cancer and 25 controls were entered in this study. Of 8 patients whose scan showed response in 12 patients with metastatic lumbar spine lesion, they had either 7 responded or 1 unchanged BMD level in the lumbar spine. Of 9 patients whose scan showed response in 15 patients with metastatic total spine lesion, they had either 6 responded or 3 unchanged BMD level in the total spine. The alterations of BMD levels in total spine and lumbar spine closely correlated with the therapeutic responses assessed by the National Prostatic Cancer Project Criteria of bone scintigraphy in patients with prostatic cancer (spine: r=0.04, p<0.05; lumbar: r=0.1, p<0.05). In contrast, BMD changes in whole body (response rate: 20.0%, P<0.05) was less than that in total spin (response rate: 53.3%, P<0.01) and lumbar spine (response rate: 58.3%, P<0.01). In conclusion, when compare BMD to the hot spot region in bone scan, BMD may be helpful to the urologist for the accuracy of the staging and evaluation of the treatment response to androgen deprivation therapy in metastatic prostate cancer.
Acid Phosphatase ; Bone Density ; Densitometry* ; Evaluation Studies as Topic ; Humans ; Prostate-Specific Antigen ; Prostatic Neoplasms* ; Radiography ; Radionuclide Imaging ; Spine

No abstract available.
Bone Marrow Cells/pathology ; Bone and Bones/radionuclide imaging ; Female ; Humans ; Lung Neoplasms/diagnosis/radiography ; Middle Aged ; Multimodal Imaging ; Multiple Myeloma/*diagnosis/pathology/radiography ; Tomography, X-Ray Computed

Osseous hemangioma is a benign vascular tumor, and it usually occurs in the vertebrae and the skull. However, hemangiomas of flat bones are rare, and there are very few reports that describe the radiologic findings of osseous hemangioma of the ilium. We report a unique case of large cavernous hemangioma mimicking a chondrogenic malignant bone tumor originated from the ilium in a 22-year-old female. The mass showed stippled calcifications, heterogeneous enhancement with thick septa and enhanced soft tissue components on CT and MR, and also this mass demonstrated heterogeneous 2-fluoro [fluorine-18]-2-deoxy-D-glucose (18F-FDG) uptake on 18F-FDG PET/CT.
Bone Neoplasms/radionuclide imaging ; Diagnosis, Differential ; Female ; Fluorodeoxyglucose F18/*diagnostic use ; Hemangioma, Cavernous/*radionuclide imaging ; Humans ; Ilium/*blood supply ; Magnetic Resonance Imaging ; Positron-Emission Tomography and Computed Tomography ; Radiopharmaceuticals/*diagnostic use ; Young Adult

OBJECTIVETo investigate the indication of bone scan for patients with newly diagnosed prostate cancer.

METHODSThe clinical data of continual 95 patients with newly diagnosed prostate cancer was involved between January 2006 and December 2010. The relationship between age, PSA, Gleason scores, clinical stage and positive bone scans was respectively compared.

RESULTSThe 33 patients (34.7%) with positive bone scans and 62 patients (65.3%) with negative bone scans. The mean age was (74±7) years and (76±7) years respectively in 2 groups respectively. PSA was (70.7±38.1) ng/ml and (28.4±27.2) ng/ml respectively, the difference was significant (t=-5.499, P=0.000). Clinical stage had positive correlation with positive bone scan, the OR value was 4.684. If the Gleason score>7, the sensitivity, specificity, positive predictive value and negative predictive value of positive bone scan was 64%, 63%, 48% and 77% respectively. If PSA>50 ng/ml, sensitivity, specificity, positive predictive value and negative predictive value was 67%, 86%, 71% and 83% respectively. If Clinical stage>T2, sensitivity, specificity, positive predictive value and negative predictive value was 82%, 81%, 69% and 89% respectively.

CONCLUSIONSFor patients with PSA≤10 ng/ml or simultaneously PSA≤50 ng/ml and Gleason score≤7 and clinical stage≤T2, bone scan is not necessary. Patients with newly diagnosed prostate cancer and PSA>50 ng/ml or Gleason score>7 or clinical stage>T2 should undergo bone scan.

Aged ; Aged, 80 and over ; Bone Neoplasms ; diagnostic imaging ; secondary ; Bone and Bones ; diagnostic imaging ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Prostatic Neoplasms ; diagnostic imaging ; pathology ; Radionuclide Imaging ; Retrospective Studies ; Sensitivity and Specificity

AIMSTo determine when a bone scan investigation is appropriate in asymptomatic men diagnosed with prostate cancer.

METHODSBetween November 2005 and July 2006, 317 men with prostate cancer underwent a bone scan study; 176 men fulfilled the inclusion criteria. Prostate-specific antigen (PSA) cut-offs as well as univariate and multivariate logistic regression analyses using digital rectal examination finding, biopsy Gleason scores and age were performed to determine when a bone scan study is likely to be of value.

RESULTSOnly 1/61 men (1.6%) with a serum PSA 20 ng/mL had a positive bone scan. However, 2/38 men (4.7%) with a serum PSA 20.1-40.0 ng/mL, 3/20 men (15%) with a serum PSA 40.1-60.0 ng/mL, 7/19 men (36.8%) with a serum PSA 60.1-100.0 ng/mL and 19/38 men (50%) with a serum PSA > 100.0 ng/mL had positive bone scans. Univariate and multivariate logistic regression analyses were uninformative in these groups.

CONCLUSIONBased on our findings, a bone scan is of limited value in asymptomatic prostate cancer patients presenting PSA =or< 20 ng/mL. Therefore, this investigation can be eliminated unless a curative treatment is contemplated. Furthermore, digital rectal examination finding, biopsy Gleason score and age are unhelpful in predicting those who might harbor bone metastasis.

Aged ; Aged, 80 and over ; Analysis of Variance ; Bone Neoplasms ; diagnostic imaging ; secondary ; Bone and Bones ; diagnostic imaging ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Prostate-Specific Antigen ; analysis ; Prostatic Neoplasms ; diagnostic imaging ; pathology ; Radionuclide Imaging ; Radiopharmaceuticals ; Retrospective Studies ; Technetium Tc 99m Medronate

Arthrography ; Bone Neoplasms ; diagnosis ; diagnostic imaging ; pathology ; Bone and Bones ; diagnostic imaging ; pathology ; Diagnosis, Differential ; Diagnostic Errors ; Humans ; Immunohistochemistry ; Joint Diseases ; diagnosis ; diagnostic imaging ; pathology ; Joints ; diagnostic imaging ; pathology ; Radionuclide Imaging